Published in Oncogene on September 20, 2001
Principles of interleukin (IL)-6-type cytokine signalling and its regulation. Biochem J (2003) 10.77
The AKT-mTOR axis regulates de novo differentiation of CD4+Foxp3+ cells. J Exp Med (2008) 6.07
CXCR4 inhibitor AMD3100 disrupts the interaction of multiple myeloma cells with the bone marrow microenvironment and enhances their sensitivity to therapy. Blood (2009) 3.37
Perifosine, an oral bioactive novel alkylphospholipid, inhibits Akt and induces in vitro and in vivo cytotoxicity in human multiple myeloma cells. Blood (2006) 3.04
BAFF and APRIL protect myeloma cells from apoptosis induced by interleukin 6 deprivation and dexamethasone. Blood (2003) 2.82
Antimyeloma activity of heat shock protein-90 inhibition. Blood (2005) 2.24
The Akt pathway regulates survival and homing in Waldenstrom macroglobulinemia. Blood (2007) 1.99
Targeting the beta-catenin/TCF transcriptional complex in the treatment of multiple myeloma. Proc Natl Acad Sci U S A (2007) 1.77
Survival and proliferation factors of normal and malignant plasma cells. Int J Hematol (2003) 1.76
Dual inhibition of canonical and noncanonical NF-κB pathways demonstrates significant antitumor activities in multiple myeloma. Clin Cancer Res (2012) 1.73
Dominant role of antigen dose in CD4+Foxp3+ regulatory T cell induction and expansion. J Immunol (2009) 1.59
Beta1 integrin adhesion enhances IL-6-mediated STAT3 signaling in myeloma cells: implications for microenvironment influence on tumor survival and proliferation. Cancer Res (2009) 1.55
The use of novel agents in the treatment of relapsed and refractory multiple myeloma. Leukemia (2009) 1.30
Interleukin-6 and its receptor, key players in hepatobiliary inflammation and cancer. Transl Gastrointest Cancer (2012) 1.26
Bone marrow microenvironment in multiple myeloma progression. J Biomed Biotechnol (2012) 1.21
A high-affinity fully human anti-IL-6 mAb, 1339, for the treatment of multiple myeloma. Clin Cancer Res (2009) 1.20
Sorafenib, a dual Raf kinase/vascular endothelial growth factor receptor inhibitor has significant anti-myeloma activity and synergizes with common anti-myeloma drugs. Oncogene (2009) 1.18
IL-6 cytoprotection in hyperoxic acute lung injury occurs via PI3K/Akt-mediated Bax phosphorylation. Am J Physiol Lung Cell Mol Physiol (2009) 1.17
The de-ubiquitinase UCH-L1 is an oncogene that drives the development of lymphoma in vivo by deregulating PHLPP1 and Akt signaling. Leukemia (2010) 1.15
Targeted inhibition of interleukin-6 with CNTO 328 sensitizes pre-clinical models of multiple myeloma to dexamethasone-mediated cell death. Br J Haematol (2008) 1.12
Impact of interleukin-6 in hematological malignancies. Transfus Med Hemother (2013) 1.11
Defining the role of TORC1/2 in multiple myeloma. Blood (2011) 1.10
From the bench to the bedside: emerging new treatments in multiple myeloma. Best Pract Res Clin Haematol (2007) 1.10
Novel phosphatidylinositol 3-kinase inhibitor NVP-BKM120 induces apoptosis in myeloma cells and shows synergistic anti-myeloma activity with dexamethasone. J Mol Med (Berl) (2011) 1.10
Interleukin-6 (IL-6) and IL-17 synergistically promote viral persistence by inhibiting cellular apoptosis and cytotoxic T cell function. J Virol (2014) 1.08
Multiple myeloma mesenchymal stem cells: characterization, origin, and tumor-promoting effects. Clin Cancer Res (2011) 1.06
Growth control of multiple myeloma cells through inhibition of glycogen synthase kinase-3. Leuk Lymphoma (2008) 1.01
Janus kinase inhibitor INCB20 has antiproliferative and apoptotic effects on human myeloma cells in vitro and in vivo. Mol Cancer Ther (2009) 1.00
Emerging treatments for multiple myeloma: beyond immunomodulatory drugs and bortezomib. Semin Hematol (2009) 1.00
Dual regulation of glucocorticoid-induced leucine zipper (GILZ) by the glucocorticoid receptor and the PI3-kinase/AKT pathways in multiple myeloma. J Steroid Biochem Mol Biol (2008) 0.99
The role of microenvironment in tumor angiogenesis. Genes Nutr (2008) 0.98
Extravasation and homing mechanisms in multiple myeloma. Clin Exp Metastasis (2007) 0.97
Selective and potent Akt inhibition triggers anti-myeloma activities and enhances fatal endoplasmic reticulum stress induced by proteasome inhibition. Cancer Res (2014) 0.97
Emerging therapies for multiple myeloma. Expert Opin Emerg Drugs (2009) 0.96
Specific activation of the glucocorticoid receptor and modulation of signal transduction pathways in human lens epithelial cells. Invest Ophthalmol Vis Sci (2007) 0.96
GCS-100, a novel galectin-3 antagonist, modulates MCL-1, NOXA, and cell cycle to induce myeloma cell death. Blood (2010) 0.95
TG101209, a novel JAK2 inhibitor, has significant in vitro activity in multiple myeloma and displays preferential cytotoxicity for CD45+ myeloma cells. Am J Hematol (2010) 0.95
Blockade of interleukin-6 signalling with siltuximab enhances melphalan cytotoxicity in preclinical models of multiple myeloma. Br J Haematol (2011) 0.95
SDX-101, the R-enantiomer of etodolac, induces cytotoxicity, overcomes drug resistance, and enhances the activity of dexamethasone in multiple myeloma. Blood (2005) 0.95
The role of activin A and Akt/GSK signaling in ovarian tumor biology. Endocrinology (2008) 0.94
Anti-myeloma activity of Akt inhibition is linked to the activation status of PI3K/Akt and MEK/ERK pathway. PLoS One (2012) 0.93
T cell-intrinsic role of IL-6 signaling in primary and memory responses. Elife (2014) 0.92
Small compound 6-O-angeloylplenolin induces mitotic arrest and exhibits therapeutic potentials in multiple myeloma. PLoS One (2011) 0.91
Novel therapeutic strategies for multiple myeloma. Exp Hematol (2015) 0.91
IL-6 negatively regulates osteoblast differentiation through the SHP2/MEK2 and SHP2/Akt2 pathways in vitro. J Bone Miner Metab (2014) 0.90
A novel selective small-molecule PI3K inhibitor is effective against human multiple myeloma in vitro and in vivo. Blood Cancer J (2013) 0.89
The bone marrow stroma in hematological neoplasms--a guilty bystander. Nat Rev Clin Oncol (2011) 0.89
The human immunodeficiency virus-1 protease inhibitor nelfinavir impairs proteasome activity and inhibits the proliferation of multiple myeloma cells in vitro and in vivo. Haematologica (2012) 0.88
Bone marrow microenvironment in myelomagenesis: its potential role in early diagnosis. Expert Rev Mol Diagn (2010) 0.87
CD28-mediated pro-survival signaling induces chemotherapeutic resistance in multiple myeloma. Blood (2014) 0.87
A novel role for the marrow microenvironment in initiating and sustaining hematopoietic disease. Expert Opin Biol Ther (2009) 0.87
New insights into purinergic receptor signaling in neuronal differentiation, neuroprotection, and brain disorders. Purinergic Signal (2007) 0.87
Cladribine and bendamustine exhibit inhibitory activity in dexamethasone-sensitive and -resistant multiple myeloma cells. Am J Transl Res (2013) 0.87
Bone marrow angiogenesis and progression in multiple myeloma. Am J Blood Res (2011) 0.87
Preclinical studies of novel targeted therapies. Hematol Oncol Clin North Am (2007) 0.86
A review of lenalidomide in combination with dexamethasone for the treatment of multiple myeloma. Ther Clin Risk Manag (2008) 0.86
Retracted Fatty acid synthase is a novel therapeutic target in multiple myeloma. Br J Haematol (2008) 0.85
IL-6 in diabetes and cardiovascular complications. Br J Pharmacol (2014) 0.85
Monocyte chemotactic protein 1 (MCP-1) modulates pro-survival signaling to promote progression of head and neck squamous cell carcinoma. PLoS One (2014) 0.84
New frontiers in the treatment of multiple myeloma. ScientificWorldJournal (2006) 0.83
Interleukin-6 gene ablation in a transgenic mouse model of malignant skin melanoma. Am J Pathol (2005) 0.82
Tetraspanin CD37 protects against the development of B cell lymphoma. J Clin Invest (2016) 0.81
Mechanisms of Drug Resistance in Relapse and Refractory Multiple Myeloma. Biomed Res Int (2015) 0.81
Anti-β₂M monoclonal antibodies kill myeloma cells via cell- and complement-mediated cytotoxicity. Int J Cancer (2014) 0.81
PI3-K/Akt pathway contributes to IL-6-dependent growth of 7TD1 cells. Cancer Cell Int (2003) 0.80
An integrin-targeted, pan-isoform, phosphoinositide-3 kinase inhibitor, SF1126, has activity against multiple myeloma in vivo. Cancer Chemother Pharmacol (2013) 0.80
Activity of everolimus (RAD001) in relapsed and/or refractory multiple myeloma: a phase I study. Haematologica (2015) 0.79
Conditioned media from mouse osteosarcoma cells promote MC3T3-E1 cell proliferation using JAKs and PI3-K/Akt signal crosstalk. Cancer Sci (2008) 0.79
Preclinical validation of interleukin 6 as a therapeutic target in multiple myeloma. Immunol Res (2014) 0.78
Inhibition of gap junctional Intercellular communication in WB-F344 rat liver epithelial cells by triphenyltin chloride through MAPK and PI3-kinase pathways. J Occup Med Toxicol (2010) 0.78
Mass cytometry analysis shows that a novel memory phenotype B cell is expanded in multiple myeloma. Cancer Immunol Res (2015) 0.77
Multiple mechanisms contribute to the synergistic anti-myeloma activity of the pan-histone deacetylase inhibitor LBH589 and the rapalog RAD001. Leuk Res (2014) 0.76
PI3Kδ and PI3Kγ isoforms have distinct functions in regulating pro-tumoural signalling in the multiple myeloma microenvironment. Blood Cancer J (2017) 0.76
Diacerein-mediated inhibition of IL-6/IL-6R signaling induces apoptotic effects on breast cancer. Oncogene (2015) 0.76
Expression of leukemia inhibitory factor in the rat retina following acute ocular hypertension. Mol Med Rep (2015) 0.76
Mechanism of action of immunomodulatory agents in multiple myeloma. Med Oncol (2010) 0.76
Multiple myeloma-derived Jagged ligands increases autocrine and paracrine interleukin-6 expression in bone marrow niche. Oncotarget (2016) 0.76
Erythropoietin treatment in murine multiple myeloma: immune gain and bone loss. Sci Rep (2016) 0.76
UCHL1 is a biomarker of aggressive multiple myeloma required for disease progression. Oncotarget (2015) 0.75
Immunostimulatory Effects of Melphalan and Usefulness in Adoptive Cell Therapy with Antitumor CD4+ T Cells. Crit Rev Immunol (2016) 0.75
Gene microarray analyses for potential biomarkers of single and recurrent venous thromboembolism. Mol Med Rep (2015) 0.75
Proteomic Characterization of the World Trade Center dust-activated mdig and c-myc signaling circuit linked to multiple myeloma. Sci Rep (2016) 0.75
The Thyroid Hormone Receptors Inhibit Hepatic Interleukin-6 Signaling During Endotoxemia. Sci Rep (2016) 0.75
Bone marrow PMN-MDSCs and neutrophils are functionally similar in protection of multiple myeloma from chemotherapy. Cancer Lett (2015) 0.75
Interleukin-6 inhibits apoptosis of exocrine gland tissues under inflammatory conditions. Cytokine (2015) 0.75
The Role of PI3K Isoforms in Regulating Bone Marrow Microenvironment Signaling Focusing on Acute Myeloid Leukemia and Multiple Myeloma. Cancers (Basel) (2017) 0.75
Arsenic trioxide-based therapy in relapsed/refractory multiple myeloma patients: a meta-analysis and systematic review. Onco Targets Ther (2014) 0.75
Novel inhibition of PIM2 kinase has significant anti-tumor efficacy in multiple myeloma. Leukemia (2017) 0.75
Overriding TKI resistance of renal cell carcinoma by combination therapy with IL-6 receptor blockade. Oncotarget (2017) 0.75
Somatic SF3B1 mutation in myelodysplasia with ring sideroblasts. N Engl J Med (2011) 7.89
The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Res (2001) 6.93
Expression of Epstein-Barr virus transformation-associated genes in tissues of patients with EBV lymphoproliferative disease. N Engl J Med (1989) 6.66
Formation of actin stress fibers and focal adhesions enhanced by Rho-kinase. Science (1997) 5.80
Phosphorylation of the PTEN tail regulates protein stability and function. Mol Cell Biol (2000) 5.22
Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma. Blood (2001) 4.76
Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy. Blood (2000) 4.37
Regulation of G1 progression by the PTEN tumor suppressor protein is linked to inhibition of the phosphatidylinositol 3-kinase/Akt pathway. Proc Natl Acad Sci U S A (1999) 4.19
Single neurons in prefrontal cortex encode abstract rules. Nature (2001) 4.05
A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma. Br J Haematol (2004) 3.49
Cdc2 kinase directly phosphorylates the cis-Golgi matrix protein GM130 and is required for Golgi fragmentation in mitosis. Cell (1998) 3.36
Phosphorylation of the PTEN tail acts as an inhibitory switch by preventing its recruitment into a protein complex. J Biol Chem (2001) 3.27
B4, a human B lymphocyte-associated antigen expressed on normal, mitogen-activated, and malignant B lymphocytes. J Immunol (1983) 3.09
Multiple myeloma cell adhesion-induced interleukin-6 expression in bone marrow stromal cells involves activation of NF-kappa B. Blood (1996) 2.98
The nucleotide sequence of the yeast PHO5 gene: a putative precursor of repressible acid phosphatase contains a signal peptide. Nucleic Acids Res (1983) 2.83
Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma. Leukemia (2007) 2.76
Expression of human B cell-associated antigens on leukemias and lymphomas: a model of human B cell differentiation. Blood (1984) 2.74
Mapping the interaction between GRASP65 and GM130, components of a protein complex involved in the stacking of Golgi cisternae. EMBO J (1998) 2.57
Fas ligand in human serum. Nat Med (1996) 2.53
Essential roles of the Fas-Fas ligand pathway in the development of pulmonary fibrosis. J Clin Invest (1999) 2.43
Targeted gene disruption of Hsp70-2 results in failed meiosis, germ cell apoptosis, and male infertility. Proc Natl Acad Sci U S A (1996) 2.40
Hypotensive reactions: a previously uncharacterized complication of platelet transfusion? Transfusion (1996) 2.37
Platelet transfusion for patients with cancer: clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol (2001) 2.33
The COOH terminus of Rho-kinase negatively regulates rho-kinase activity. J Biol Chem (1999) 2.32
Adherence of multiple myeloma cells to bone marrow stromal cells upregulates vascular endothelial growth factor secretion: therapeutic applications. Leukemia (2001) 2.30
Multiple myeloma: increasing evidence for a multistep transformation process. Blood (1998) 2.29
Bone marrow microenvironment and the identification of new targets for myeloma therapy. Leukemia (2008) 2.29
Induction of coronary artery spasm by acetylcholine in patients with variant angina: possible role of the parasympathetic nervous system in the pathogenesis of coronary artery spasm. Circulation (1986) 2.17
Vam3p, a new member of syntaxin related protein, is required for vacuolar assembly in the yeast Saccharomyces cerevisiae. J Cell Sci (1997) 2.05
The role of tumor necrosis factor alpha in the pathophysiology of human multiple myeloma: therapeutic applications. Oncogene (2001) 2.04
The role of MDM2 in the proliferative activity of ameloblastoma. Oral Oncol (2002) 2.04
Adhesion of human myeloma-derived cell lines to bone marrow stromal cells stimulates interleukin-6 secretion. Blood (1993) 2.02
Solitary fibrous tumour: significance of p53 and CD34 immunoreactivity in its malignant transformation. Histopathology (1998) 2.00
Depletion of RT6.1+ T lymphocytes induces diabetes in resistant biobreeding/Worcester (BB/W) rats. J Exp Med (1987) 1.93
A novel Bcl-2/Bcl-X(L)/Bcl-w inhibitor ABT-737 as therapy in multiple myeloma. Oncogene (2006) 1.89
Ascorbic acid inhibits antitumor activity of bortezomib in vivo. Leukemia (2009) 1.84
Bortezomib appears to overcome the poor prognosis conferred by chromosome 13 deletion in phase 2 and 3 trials. Leukemia (2006) 1.79
Atypical adenomatous hyperplasia and bronchoalveolar lung carcinoma. Analysis by morphometry and the expressions of p53 and carcinoembryonic antigen. Am J Surg Pathol (1996) 1.77
Plasma cell leukemia: consensus statement on diagnostic requirements, response criteria and treatment recommendations by the International Myeloma Working Group. Leukemia (2012) 1.74
Phosphorylation of collapsin response mediator protein-2 by Rho-kinase. Evidence for two separate signaling pathways for growth cone collapse. J Biol Chem (2000) 1.73
Nonsurgical treatment of duodenal perforation by endoscopic repair using a clipping device. Gastrointest Endosc (1999) 1.72
Myosin II activation promotes neurite retraction during the action of Rho and Rho-kinase. Genes Cells (1998) 1.71
Nucleotide sequence coding for the insecticidal fragment of the Bacillus thuringiensis crystal protein. Gene (1985) 1.70
Management of treatment-emergent peripheral neuropathy in multiple myeloma. Leukemia (2011) 1.70
IL-6 triggers cell growth via the Ras-dependent mitogen-activated protein kinase cascade. J Immunol (1997) 1.68
Storage in an organic solvent as a means for preserving viability of pollen grains. Stain Technol (1972) 1.67
Golgi division and membrane traffic. Trends Cell Biol (1998) 1.66
Gene transfer in utero biologically engineers a patent ductus arteriosus in lambs by arresting fibronectin-dependent neointimal formation. Nat Med (1999) 1.64
High-dose chemoradiotherapy and anti-B-cell monoclonal antibody-purged autologous bone marrow transplantation in mantle-cell lymphoma: no evidence for long-term remission. J Clin Oncol (1998) 1.61
History of the development of arsenic derivatives in cancer therapy. Oncologist (2001) 1.61
The AtVAM3 encodes a syntaxin-related molecule implicated in the vacuolar assembly in Arabidopsis thaliana. J Biol Chem (1997) 1.60
Anti-CD38-blocked ricin: an immunotoxin for the treatment of multiple myeloma. Blood (1994) 1.59
TRAIL/Apo2L ligand selectively induces apoptosis and overcomes drug resistance in multiple myeloma: therapeutic applications. Blood (2001) 1.59
Unique association of p53 mutations with undifferentiated but not with differentiated carcinomas of the thyroid gland. Cancer Res (1992) 1.57
Real-Time polymerase chain reaction of immunoglobulin rearrangements for quantitative evaluation of minimal residual disease in multiple myeloma. Biol Blood Marrow Transplant (2000) 1.57
Vascular endothelial growth factor triggers signaling cascades mediating multiple myeloma cell growth and migration. Blood (2001) 1.57
Lenalidomide inhibits osteoclastogenesis, survival factors and bone-remodeling markers in multiple myeloma. Leukemia (2008) 1.56
Transfusions enriched for W3/25+ helper/inducer T lymphocytes prevent spontaneous diabetes in the BB/W rat. Diabetologia (1987) 1.55
Second-look arthroscopy after meniscal repair. Review of 132 menisci repaired by an arthroscopic inside-out technique. J Bone Joint Surg Br (1995) 1.54
Minor clone provides a reservoir for relapse in multiple myeloma. Leukemia (2012) 1.54
Toxicity and efficacy of defined doses of CD4(+) donor lymphocytes for treatment of relapse after allogeneic bone marrow transplant. Blood (1998) 1.52
B cell origin of non-T cell acute lymphoblastic leukemia. A model for discrete stages of neoplastic and normal pre-B cell differentiation. J Clin Invest (1984) 1.51
Cytoskeletal rearrangements and transcriptional activation of c-fos serum response element by Rho-kinase. J Biol Chem (1997) 1.48
Cytodifferentiation of atypical adenomatous hyperplasia and bronchioloalveolar lung carcinoma: immunohistochemical and ultrastructural studies. Virchows Arch (1997) 1.47
Brief report: graft-versus-host disease associated with transfusion of blood from unrelated HLA-homozygous donors. N Engl J Med (1993) 1.46
A pivotal role for Mcl-1 in Bortezomib-induced apoptosis. Oncogene (2007) 1.46
Efficacy and safety of bortezomib in patients with renal impairment: results from the APEX phase 3 study. Leukemia (2008) 1.46
Posttransfusion graft-versus-host disease in Japanese newborns. Transfusion (1996) 1.44
Leukocyte reduction in blood component therapy. Ann Intern Med (1992) 1.44
Interstitial pneumonia in Hermansky-Pudlak syndrome: significance of florid foamy swelling/degeneration (giant lamellar body degeneration) of type-2 pneumocytes. Virchows Arch (2000) 1.44
In vivo infection of human T-cell leukemia virus type I in non-T cells. Virology (1993) 1.43
Cephalometric comparison of craniofacial morphology between primary bone grafted and nongrafted complete unilateral cleft lip and palate adults. Cleft Palate Craniofac J (1996) 1.43
The development of a model for the homing of multiple myeloma cells to human bone marrow. Blood (1997) 1.42
Trichotillomania and trichophagia leading to trichobezoar. J Dermatol (2000) 1.41
Continuous-sterilization system that uses photosemiconductor powders. Appl Environ Microbiol (1988) 1.41
Antigens on human plasma cells identified by monoclonal antibodies. J Immunol (1983) 1.41
Fusion using fast heating of a compactly imploded CD core. Phys Rev Lett (2012) 1.40
miR-29b sensitizes multiple myeloma cells to bortezomib-induced apoptosis through the activation of a feedback loop with the transcription factor Sp1. Cell Death Dis (2012) 1.40
A unique three-dimensional SCID-polymeric scaffold (SCID-synth-hu) model for in vivo expansion of human primary multiple myeloma cells. Leukemia (2011) 1.38
Low sensitivity of ELISA testing in early HIV infection. N Engl J Med (1986) 1.37
Interleukin-6 inhibits Fas-induced apoptosis and stress-activated protein kinase activation in multiple myeloma cells. Blood (1997) 1.37
Lifestyle, obesity, and insulin resistance. Diabetes Care (2001) 1.36
Studies of in vitro activation and differentiation of human B lymphocytes. I. Phenotypic and functional characterization of the B cell population responding to anti-Ig antibody. J Immunol (1985) 1.35
A Di-leucine signal in the ubiquitin moiety. Possible involvement in ubiquitination-mediated endocytosis. J Biol Chem (2000) 1.35